Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-742X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings ; volume:48 ; number:4 ; day:20 ; month:8 ; year:2019 ; pages:653-660 ; date:11.2019
Journal of thrombosis and thrombolysis ; 48, Heft 4 (20.8.2019), 653-660, 11.2019
- Creator
-
Ikeda, Takanori
Ogawa, Satoshi
Kitazono, Takanari
Nakagawara, Jyoji
Minematsu, Kazuo
Miyamoto, Susumu
Murakawa, Yuji
Iwashiro, Sanghun
Kidani, Yoko
Okayama, Yutaka
Sunaya, Toshiyuki
Sato, Shoichiro
Yamanaka, Satoshi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11239-019-01934-6
- URN
-
urn:nbn:de:101:1-2020021501372013308464
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ikeda, Takanori
- Ogawa, Satoshi
- Kitazono, Takanari
- Nakagawara, Jyoji
- Minematsu, Kazuo
- Miyamoto, Susumu
- Murakawa, Yuji
- Iwashiro, Sanghun
- Kidani, Yoko
- Okayama, Yutaka
- Sunaya, Toshiyuki
- Sato, Shoichiro
- Yamanaka, Satoshi
- SpringerLink (Online service)
Other Objects (12)
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Initial rivaroxaban dosing in patients with atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Initial rivaroxaban dosing in patients with atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Initial rivaroxaban dosing in patients with atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis